Overview

Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether taking the medication memantine reduces impairment of memory and attention associated with electroconvulsive therapy.
Phase:
N/A
Details
Lead Sponsor:
Stanford University
Collaborator:
Forest Laboratories
Treatments:
Memantine